Here, there was no correlation between OSI-906 sensitivity and total/activated IGF-1R in the melanoma cell lines, and no evidence that downstream pathway activation due to PTEN loss, BRAF or NRAS mutation was associated with IGF-1Ri resistance, consistent with our previous data using IGF1R gene silencing [11]. This evidence concerns the gene NRAS and melanoma.